114
Views
14
CrossRef citations to date
0
Altmetric
Clinical Research Articles

Reboxetine in therapy-resistant enuresis: A retrospective evaluation

&
Pages 365-368 | Received 17 Mar 2009, Published online: 18 Nov 2009
 

Abstract

Objective. Imipramine is the only evidence-based treatment available for enuretic children resistant to standard therapy. The drug's antienuretic effect is probably due to noradrenergic facilitation. The drug is, however, potentially cardiotoxic. In this study, the non-cardiotoxic noradrenergic antidepressant reboxetine was tested as an alternative to imipramine. Patients and methods. 61 patients, aged 7–19 years, with enuresis-resistant to desmopressin, the alarm, urotherapy and anticholinergics, were given 4–8 mg reboxetine at bedtime, if necessary combined with desmopressin. Results. 32 patients became dry on reboxetine treatment, although 21 of them required combination treatment with desmopressin to achieve this. Eighteen children did not respond and eight children discontinued because of side-effects before treatment could be evaluated. No serious adverse events occurred. Conclusions. These results need to be confirmed with randomized controlled studies, but indicate that reboxetine will become a safe and efficient treatment alternative for enuretic children resistant to standard therapy.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access
  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart
* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.